Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
AssigneeJanssen Biotech, Inc.
InventorsDiane D. Harrison, Elizabeth C. Hsia, Lee-Lian Kim, Kim Hung Lo
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the safe and effective treatment of active Psoriatic Arthritis (PsA).
Claims10
A method for treating a TNF related condition, wherein the TNF related condition is active Psoriatic Arthritis, the method comprising:
- administering a composition comprising a safe and effective amount of at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37, and at least one pharmaceutically acceptable carrier or diluent, wherein said composition is administered via IV infusion, and wherein at week 14 of treatment patients treated with the anti-TNF antibody achieve a mean change from baseline in one or more criteria selected from the group consisting of:
- HAQ-DI=−0.60±0.53 SD, enthesitis=−1.87±1.75 SD, dactylitis=−7.8±8.57 SD, SF-36 PCS=8.65±7.60 SD, and SF-36 MCS=5.33±9.95 SD.
A method for treating a TNF related condition, wherein the TNF related condition is active Psoriatic Arthritis, the method comprising:
- administering a composition comprising a safe and effective amount of at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37, and at least one pharmaceutically acceptable carrier or diluent, wherein said composition is administered via IV infusion, and wherein at week 24 of treatment patients treated with the anti-TNF antibody achieve a mean change from baseline in vdH-S=−0.36±0.144 SE.
A method for treating a TNF related condition, wherein the TNF related condition is active Psoriatic Arthritis, the method comprising:
- administering a safe and effective amount of at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37, wherein said anti-TNF antibody is administered via intravenous (IV) infusion, and wherein ≥65% of patients receiving the treatment achieve ACR20 at week 14 of treatment.
Dependencies are inferred from the claim text.